Protective effects of p-coumaric acid against high-fat diet-induced metabolic dysregulation in mice.
Adiposity
/ drug effects
Animals
Anti-Inflammatory Agents
/ pharmacology
Antioxidants
/ pharmacology
Blood Glucose
/ drug effects
Coumaric Acids
/ pharmacology
Diet, High-Fat
/ adverse effects
Inflammation
/ prevention & control
Insulin Resistance
Male
Mice
Mice, Inbred C57BL
Non-alcoholic Fatty Liver Disease
/ prevention & control
Obesity
/ prevention & control
Resistin
/ blood
High-fat diet
Inflammation
Insulin resistance
Non-alcoholic fatty liver disease
Obesity
p-Coumaric acid
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
06
05
2021
revised:
16
07
2021
accepted:
23
07
2021
pubmed:
2
8
2021
medline:
7
1
2022
entrez:
1
8
2021
Statut:
ppublish
Résumé
p-Coumaric acid (PC), a naturally occurring phytochemical, possesses antioxidant and anti-inflammatory properties; however, the mechanisms underlying its protective effects against obesity-related metabolic dysfunction are largely unknown. Here, we treated C57BL/6J mice to a high-fat diet (HFD) with or without PC (10 mg/kg body weight/day) for 16 weeks to determine whether PC ameliorates HFD-induced obesity, insulin resistance, inflammation, and non-alcoholic fatty liver disease (NAFLD). We found no significant differences in food intake and body weight between the groups. However, PC-treated mice showed significantly lower white adipose tissue (WAT) weight, adipocyte size, and plasma leptin level, which were associated with decreased lipogenic enzyme activity and mRNA expression of their genes in the epididymal WAT. Moreover, hepatic lipogenic enzymes activities and expression of their genes and proteins were decreased with concomitant increases in hepatic fatty acid oxidation and mRNA expression of its gene; fecal lipid excretion was significantly increased, resulting in decreased liver weight, hepatic lipid levels, lipid droplet accumulation, and plasma aspartate aminotransferase and lipid levels. Additionally, PC-treated mice showed lower fasting blood glucose, plasma resistin, and MCP-1 levels, HOMA-IR, and mRNA expression of inflammatory genes in the epididymal WAT and liver. Our findings reveal potential mechanisms underlying the action of PC against HFD-induced adiposity, NAFLD, and other metabolic disturbances.
Identifiants
pubmed: 34333285
pii: S0753-3322(21)00751-4
doi: 10.1016/j.biopha.2021.111969
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Antioxidants
0
Blood Glucose
0
Coumaric Acids
0
Resistin
0
p-coumaric acid
IBS9D1EU3J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111969Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.